DealsJun 1, 2026, 05:01 AM
Agios Licenses Global Rights to Cevidoplenib for ITP; $25M Upfront
AI Summary
Agios Pharmaceuticals secured exclusive global rights to cevidoplenib, a late-stage, next-generation oral SYK inhibitor, from Oscotec. This strategic licensing agreement expands Agios' rare hematology portfolio into immune thrombocytopenia (ITP), a rare autoimmune blood disorder, with potential for up to $1 billion in peak U.S. sales. Agios will make an upfront payment of $25.0 million to Oscotec, with additional payments tied to development, regulatory, and commercial milestones, plus tiered royalties. The company plans to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following positive Phase 2 data.
Key Highlights
- Agios obtained exclusive global rights to cevidoplenib from Oscotec.
- Agios will make a $25.0 million upfront payment to Oscotec.
- Oscotec is eligible for up to $140.0 million in development and regulatory milestones.
- Tiered royalties from high single digit to mid-teen on future net sales.
- Cevidoplenib has potential for up to $1 billion in peak U.S. sales.
- Agios expects to advance cevidoplenib into Phase 3 development in H1 2028.
- 2026 operating expense guidance remains flat, excluding the $25.0M upfront payment.
Price Impact
More from AGIO